ARTICLE | Clinical News

Remicade infliximab anti-TNF chimeric monoclonal antibody regulatory update

August 20, 2001 7:00 AM UTC

JNJ's Centocor Inc. subsidiary (Malvern, Penn.) said it is revising the label for Remicade for rheumatoid arthritis (RA) to warn that its use may increase the risk of developing tuberculosis (TB) or other infectious diseases. The revised label includes a black box warning instructing that patients should be evaluated for latent TB with a skin test, and strengthens warnings about the risk of serious infections. ...